The meaning of viral kinetics in the beginning of the pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C;Význam virové kinetiky v počátcích léčby chronické hepatitidy C pegylovaným interferonem α a ribavirinem

Vnitrni Lekarstvi

Volumn 52, Issue 2, 2006, Pages 153-159

  Husa, Petr ^a   Slesinger P ^a   Stroblova H ^a   Svobodnik A ^b  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Chronic hepatitis C; Pegylated interferon; Ribavirin; Sustained viral response; Viral kinetics

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

ADULT; AGED; ARTICLE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; MICROBIAL KINETICS;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; VIREMIA;

EID: 33644883062     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Němeček V. Sérologický přehled ČR v roce 2001 - virová hepatitida A, B, C. Zprávy CEM 2003; 12: 55-61.
2. Urbánek P. Infekce virem hepatitidy C. Praha: Galén 2004.
3. Husa P. Virové hepatitidy. Praha: Galén 2005.
4. Stránský J, Skřivánková J. Závažné vedlejší účinky při kombinované léčbě interferonem alfa a ribavirinem u pacientů s chronickou hepatitidou C. Vnitř Lék 2002; 47(1): 56-59.
5. Strader DFB, Wright T, Thomas DL et al. Diagnosis, management, and treatment of hepatitis C. AASLD Practice Guideline. Hepatology 2004; 39: 1147-1171.
6. Urbánek P, Husa P, Šperl J et al. Diagnostika a léčba chronické hepatitidy C. Doporučený postup České hepatologické společnosti a Společnosti infekčního lékařství ČLS JEP. Vnitř Lék 2005; 51(11): 1307-1313.
7. Neumann AU. Hepatitis C virus dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 228: 103-107.
8. Zeuzem S, Lee J-H, Franke A et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology 1998; 27: 1149-1156.
9. Neumann AU, Lam NP, Ahari H et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Inf Dis 2000; 182: 28-35.
10. Zeuzem S, Herrmann E, Lee JH et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alfa-2a. Gastroenterology 2001; 120: 1438-1447.
11. Husa P, Chalupa P, Štroblová H. Výsledky sérotypizace u pacientů s chronickou infekcí virem hepatitidy C. Klin Mikrobiol Inf Lék 1998; 4: 137-140.
12. Pawlotsky JM. Treatment of hepatitis C: Different by design viral kinetics: Logic in practice. The Hepatitis C Forum. Rhodos, 19. - 22. 9. 2002. Abstract book, 12-13.
13. Fried MW, Shiffmann ML, Reddy KR et al. Combination of peginterferon alfa-2a plus ribavirin in patients with chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
14. Ferenci P, Fried M, Schiffman, ML et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43: 425-433.
15. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
16. Davis GL, Wong JB, McHutchison JG et al. Early virology response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-652.